Zimmer completes Can$50m ORTHOsoft swoop:
This article was originally published in Clinica
Executive Summary
Zimmer has been successful in its acquisition of ORTHOsoft after acquiring 91% of the computer-assisted surgery (CAS) specialist's shares. The deal, which is expected to close in November, will see Zimmer purchase all outstanding shares for Can$1.10 ($1) per share, a total value of Can$50m. ORTHOsoft (Montreal, Canada) will provide Zimmer with its complementary technology designed to increase accuracy in hip, knee and spine implant surgery. The company will be integrated with Zimmer's existing CAS business but will maintain its operating facility in Montreal.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.